Genex Pharmaceutical, Inc.
GENX · OTC
12/31/2007 | 9/30/2007 | 6/30/2007 | 3/31/2007 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | -0.51 | 0.00 | 0.22 |
| FCF Yield | 0.08% | 2.50% | 4.54% | 3.62% |
| EV / EBITDA | 36.00 | 79.72 | 17.78 | 12.60 |
| Quality | ||||
| ROIC | 2.22% | 0.84% | 2.50% | 3.77% |
| Gross Margin | 90.43% | 91.56% | 86.67% | 85.73% |
| Cash Conversion Ratio | -0.07 | 3.41 | 1.23 | 0.65 |
| Growth | ||||
| Revenue 3-Year CAGR | 9.12% | 7.74% | 4.45% | 1.63% |
| Free Cash Flow Growth | -97.93% | 3.00% | 50.65% | -4.89% |
| Safety | ||||
| Net Debt / EBITDA | -3.26 | -4.88 | -2.18 | -0.29 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.18 | 0.15 | 0.23 | 0.23 |
| Cash Conversion Cycle | -93.01 | 565.49 | 1,130.06 | 1,109.78 |